Regenerex Pharma (RGPX) Cost of Revenue (2013 - 2023)

Regenerex Pharma (RGPX) has 7 years of Cost of Revenue data on file, last reported at $3000.0 in Q2 2023.

• Cost of Revenue for Q2 2023 came in at $3000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $4130.0 (changed N/A YoY), and the FY2020 annual result was $1712.0, changed N/A from the prior year.
• Cost of Revenue climbed to $3000.0 in Q2 2023 per RGPX's latest filing, from $300.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $14296.0 in Q2 2019 and troughed at $8.0 in Q2 2020.
• A 5-year average of $2069.2 and a median of $488.0 in 2020 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2020 and 2021: Cost of Revenue tumbled 99.94% in 2020, then surged 30812.5% in 2021.
• A 5-year view of Cost of Revenue shows it stood at $1570.0 in 2019, then sank by 76.82% to $364.0 in 2020, then soared by 68.13% to $612.0 in 2021, then plunged by 50.98% to $300.0 in 2022, then jumped by 900.0% to $3000.0 in 2023.
• Business Quant data shows RGPX's Cost of Revenue at $3000.0 in Q2 2023, $300.0 in Q4 2022, and $612.0 in Q4 2021.